Yes! Give Me Access to the Videos Now

Enter your email below to get instant access to video 1 in our FREE training series

We process your personal data as stated in our Privacy Policy. You may withdraw your consent at any time by clicking the unsubscribe link at the bottom of any of our emails.

Close

Where the NEW bioPHARMA INDUSTRY begins...

Join Us October 1st To Learn How Synthetic Biology Is Reimagining The Pharma Industry

How is synthetic biology going to disrupt the biopharma industry? How can synthetic biology accelerate your products? Meet the people, companies, and ideas that will transform how we pursue biopharma R&D in the coming bioeconomy.

Raul Dhanda of Sherlock Biosciences speaks at the Global Synthetic Biology Conference in San Francisco 2019

Previously featured on:

Synthetic Biology techcrunch
NY times transparent-John-cumbers
San Francisco Business Times Synthetic Biology
la times transparent-synthetic biology

Discover How Synthetic Biology is Disrupting Biopharma...

SynBioBeta's world-class content is matched by the best-in-class digital experience, with even more ways to connect and engage with the people, companies, and ideas that matter most to you.

Come learn the latest technologies, hear the big announcements in the field, make new partnerships, meet investors, and discover new companies.

October 1st, 2020

Faster, Better, Cheaper Medicine


The pandemic has spurred many new collaborations between synthetic biology and pharma companies. Learn from leading innovators about how synthetic biology has accelerated development in diagnostics, therapies, and vaccines from years to weeks.

Partnerships At A Whole New Level


With AI-powered networking and interactive features only available through our digital experience, you'll engage and connect with just the right people in synthetic biology, health, academia, the investment community, policy, and more.

Emerging Technology Platforms


Biopharma Day is your one-stop shop for the most cutting-edge synthetic biology platforms. Hear about the latest tools and technologies as they unfold and accelerate product timelines for coronavirus and much, much more.

50+

Speakers

15+

Breakout Sessions

John-Cumbers-SynBioBeta-2020

About Your Host

JOHN CUMBERS

FOUNDER, SYNBIOBETA

Hi, my name is John, and I am the founder of SynBioBeta. We help bio-entrepreneurs, companies, investors, researchers, visionaries, and thought leaders who are shaping the future of humanity to connect and bring projects to life.


This year I am proud to bring together the synthetic biology industry and biopharma industry like never before. I can't wait to see you there!

The global synthetic biology conference is here

Explore Some Of Our Groundbreaking Sessions

Synthetic Biology Versus Cancer

Synthetic biology approaches are rapidly advancing cancer therapies and transforming how we care for patients. With trials underway to bring living medicines and new immunotherapy solutions online, synthetic biology is poised to transform the landscape of healthcare and medicine. This session will explore the latest innovations and applications, technical challenges, and perspectives from leading innovators.

Pandemic Response: Scaling and Collaborating in the Face of the Coronavirus

COVID-19 has challenged our community to deliver new diagnostic platforms, production processes, and therapeutic modalities. What has COVID taught us about going from concept to solution at speed? What are the realities of making these solutions robust and economically viable, often in partnership with others? From drug makers to technology providers, this session brings together diverse perspectives on vaccines, diagnostics, and novel therapeutics in the pandemic response.

The Microbiome: From Decoding Nature To Biotech Breakthroughs

Interest in the human microbiome—the ≈2 kilos and trillions of diverse bacteria that inhabit the large intestine—isn’t just hype or a natural healing trend. A significant uptick in basic science is studying the complex relationship between the microbiome, hormones, nervous and immune system, and beyond. While we turn insights into action, will interest in microbiome health fade or accelerate? We’ll look at the latest in microbiome research, explore our complex relationships with natural versus engineered treatments, and how the two might co-exist.

Engineering Live Medicines For Chronic Diseases

Living medicines, broadly speaking, are modified living biotherapeutics. The term “living” is very important because they’re designed to sense and respond to cues in the human body, then deliver optimal treatment to the specific needs of the patient. They provide treatment at exactly the right dosage, time, and place. It is designed to be smart so it is potentially more powerful and effective than conventional drugs today. In this session, we will hear from the innovators in the field about the latest advances and what's coming next.

AI and Pharma: Synthetic biology's sweet spot

Using synthetic biology to design new drugs is still a new thought process, but small and fast-moving innovators already have access to extremely powerful tools in AI, automation, and gene read/write/edit that are changing the pharma landscape. These innovators are not only reducing the time and cost to market, but more importantly bring patients with rare and undertreated diseases hope as small targets become more economically viable. This session profiles four such innovators at the forefront of AI, synbio, and pharma.

"Discover what it means to be at the frontier of innovation in the biopharma industry. Let synthetic biology be the platform that accelerates your product pipeline." 

The Antibodies Update: Promise, Progress and Lessons learned

Whether it’s testing, treatment, or vaccine development, antibodies are at the center of the research community’s race to put coronavirus behind us. Our distinguished panel in conversation about the latest antibody developments in the fight against COVID-19. We'll discuss breakthroughs, bottlenecks, tech and regulatory hurdles, and the challenges to scale-up.

Cell-free Avenues For Accelerating Forward Engineering in Pharma and Beyond

Cell-free engineering offers an opportunity to decouple the cell’s objectives from our engineering objectives. With new tools and methods for assembling and amplifying genome-scale DNA in vitro, cloning may finally become a thing of the past, not only compressing research times but also expanding what’s possible. This panel will explore the state of the art in cell-free technologies and share some surprising new ways they can be used in therapeutics, cheap diagnostics, and distributed manufacturing.

Featured Speakers

Meet the featured speakers of the Global Synthetic Biology Conference 2020

Aaron Sato

CSO

Twist Bioscience

Aaron leads Twist Biosciences' biopharma vertical, where he's combining advances in synthesis and antibody engineering. His career has taken him though a number of drug discovery companies, and he knows first-hand many of the bottlenecks in drug development. 

Jasmina Aganovic

President

Ginkgo Bioworks

Jasmina works with the powerful Ginkgo Foundry platform to see what we can learn from nature and can harness through microbes for use in the personal care and health. Her goal is to fuel a future with new types of ingredients and products, perhaps even some that we can't yet imagine.


Mike Jewett

Professor

Northwestern University

A recognized leader in cell-free research, Michael leads Northwestern University's Center for Synthetic Biology. He is a serial company founder looking to the future of pharma and manufacturing, where products are unconstrained by the cell.


Gordon Ringold

CEO

Quadriga Biosciences

Gordon is a biotechnology entrepreneur, and Quadriga is an oncology start-up focused on developing targeted anti-cancer drugs. He is on the board of directors for bio-informatics company Maverix Biomics,  as well as Ardelyx, Alexza, and 3V Biopharma.

Timothy Lu

Co-Founder & CEO

Senti Biosciences

Tim is a pioneer in synthetic biology, and an Associate Professor at MIT. He is a co-founder of Synlogic  Tango Therapeutics, Sample6, Eligo, BiomX, and Engine Biosciences. He applies synthetic biology to current immuno-oncology approaches for greater precision and effectiveness. 


Leah Sibener

Co-Founder, Therapeutic Discovery

3T Biosciences

Leah is a co-founder and the Head of Therapeutic Discovery at 3T Biosciences, and immunotherapy company that discovers novel targets and therapeutics with curative potential for solid tumor patients. She's identifying new immunotherapy targets and T-cell receptors for next-generation cell therapies.

Nathaji Gallage

Co-Founder & CEO

Octarine Bio

Nethaji leads Octarine’s mission to harness synthetic biology to develop functionally superior cannabinoid and psilocybin derivatives for pharma and health. Octarine's in-cell enzymatic platform expands chemical diversity for molecules with improved chemical & pharmacokinetic properties. 


Michael Freeman

Research Associate

Raymond James Financial, Inc.

A chemical engineer by training, Michael’s coverage of the cannabis sector focuses on its pure scientific, engineering, and clinical developments, yielding an evidence-driven, hyperbole-free perspective for the capital markets. Heterologous cannabinoid biosynthesis and synthetic biology are a cornerstone of his research.


Ena Cratsenburg

Chief Business Officer

Ginkgo Bioworks

Ena is the Chief Business Officer at Ginkgo Bioworks and has more than a decade of experience working in the industry with companies like Amyris, Evolva, Intrexon and Pixar. She oversees new business partnerships and the commercialization of Ginkgo’s technology and products. 


Sarah Ives

Director of Contract Research

Distributed Bio

Sarah Ives is an immune engineer. She leads the broad-spectrum Centivax flu vaccine program, and 50+ discovery campaigns for biotechnology and pharmaceutical companies across the globe. Sarah and her research are featured prominently in the Netflix docuseries "Pandemic: How to Prevent an Outbreak." 

Janice Chen

Co-Founder & Chief Research Officer

Mammoth Biosciences

At Mammoth, Janice is harnessing CRISPR for rapid and affordable disease detection for coronavirus and beyond. A student under CRISPR pioneer Jennifer Doudna, Chen studied how DNA-cutting CRISPR proteins recognize & cut their target, thus enabling more precise gene-editing tools. 


Rachel Haurwitz

Co-Founder, President & CEO

Caribou Biosciences

Rachel founded and has lead  Caribou since 2011. She is also a co-founder of Intellia Therapeutics. In 2014, she was named by Forbes Magazine to the "30 Under 30" list in Science and Healthcare, and in 2016, Fortune Magazine named her to the "40 Under 40" list of the most influential young people in business. 


GET YOUR TICKET TODAY

Better R&D - More Synthetic Biology

Come learn the latest technologies, hear the big announcements in the field, make new partnerships, meet investors, and discover new companies that can accelerate your drug discovery & drug manufacturing.

Connect with Thought Leaders

Step 1

Get inspired and connected to the thought leaders of the industry. Understand where the industry is going so you can stay ahead.

Connect with Talent

Step 1

Get the opportunity to showcase your company with the most talented people in the biopharma industry.

Built with Biology

Step 1

Learn how our industry can work together to promote thoughtful policies, meaningful public engagement, equitable outcomes, and a vibrant economy

Smart AI Networking

Step 1

Our apps smart AI networking optimizes your networking matches. You will use less time searching and more time to actually connect with the right fit.

Explore Latest Technology

Step 1

SynBioBeta puts you at the center of bio-innovation. See the latest technologies unfolding, all in one place.

Live Streaming

Step 1

Our virtual event platform brings you the same interactive events you’ve come to know and love, adding features only possible through a digital experience.

What Our Attendees Say About Us...

Revolutionary

“SynBioBeta is the only synthetic biology conference that pays tribute to strong science and also strong business.”

Karl Handelsman Synbiobeta

Karl Handelsman

Roche Venture Fund

Revolutionary

“We made several valuable connections, including two potential investors, and a number of future customers.”

Bethan Wolfenden Synbiobeta

Bethan Wolfenden

Founder, Bento Labs

Awesome

“A conference not to be missed – this is the place for SynBioBeta power users, experts, key opinion leaders, investors, vendors, students and novices.” 

Emily Leproust Synthetic Biology Conference

Emily Leproust

CEO, Twist Bioscience

Amazing

“SynBioBeta keeps getting better! There is no place that brings together such a crowd of scientists, entrepreneurs, investors, and thought leaders from fortune 500 companies."

Alexandre Zanghellini

Founder & CEO, Arzeda

More content than you can ever imagine

What To Expect In Our Virtual Event


Breakout Sessions

Step 1

Go deep in these sessions together with diverse, unique voices. The SynBioBeta App brings you new and exciting ways of experiencing the talks and interacting with speakers.

Keynotes

Step 1

Get insights and unique perspective from some of today’s leading thinkers and practitioners on pushing the envelope of our field, speaking to a community of peers.

Lightning Talks

Step 1

Our lightning talks are 4-minute presentations followed by live Q&A, and quickly introduce you to a diverse range of engineers, investors, entrepreneurs, and stakeholders.

Panels

Step 4

Our live panel discussions feature leading experts in conversation about the big issues impacting our industry and the bioeconomy. Hear the latest insights here, first.

Our Partners Include:

Ginko Bioworks Conference
Procter & Gamble Synthetic Biology Conference
Molecular Assemblies Synthetic Biology Conference
Codexis Synthetic Biology Conference
Strateos Synthetic Biology Conference

Agenda

Get a sneak peek of this year's amazing sessions!

FAQ

Where will the event be hosted?

ddf The conference will take place on the SynBioBeta platform, available on mobile devices through the App Store and Google Play (search “SynBioBeta”) and through the desktop version.

Will there be an exhibit hall this year?

The conference will take place on the SynBioBeta platform, available on mobile devices through the App Store and Google Play (search “SynBioBeta”) and through the desktop version.

Will I be able to network with other attendees?

Yes! In fact, networking will be optimized through the use of AI technology. The platform will suggest connections to others based on your own interests in people, sessions, and topics. You can make face-to-face appointments through the platform or connect using the interactive chat.

All Speakers

Explore and connect with our many speakers that are leading the bioeconomy

Copyright 2020 © SynBioBeta. All Rights Reserved.